Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human collagen hydrogel is a biomaterial composed of laboratory-produced (recombinant) human collagen proteins formulated into a three-dimensional, water-rich gel. These hydrogels are engineered to mimic the natural extracellular matrix and provide structural support for tissue regeneration. They promote wound healing by stimulating cell proliferation, migration, angiogenesis (formation of new blood vessels), and enhanced deposition of native collagen[1][2][6]. Recombinant technology allows for high purity and batch-to-batch consistency compared to animal-derived collagens[4]. The hydrogels can be tailored with different types of recombinant human collagens (such as type I or III) and may be combined with other bioactive components or cells. Mechanistically, they act as scaffolds that facilitate tissue repair and can also serve as "sponges" to absorb toxic metabolites such as methylglyoxal after myocardial infarction[3]. Applications include chronic wound care (e.g., diabetic ulcers), skin injury repair, cardiac tissue regeneration post-myocardial infarction, and broader uses in regenerative medicine[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human collagen hydrogel.